On Friday, Cue Biopharma Inc (NASDAQ: CUE) was 27.52% up from the session before settling in for the closing price of $1.09. A 52-week range for CUE has been $0.45 – $3.20.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
A company in the Healthcare sector has jumped its sales by 153.53% annually for the last half of the decade. When this article was written, the company’s average yearly earnings per share was at 33.69%. With a float of $62.87 million, this company’s outstanding shares have now reached $63.35 million.
In an organization with 53 employees, it is important to assess its efficiency. In terms of profitability, gross margin is -17.81%, operating margin of -477.77%, and the pretax margin is -468.02%.
Cue Biopharma Inc (CUE) Insider Updates
Also, it is sometimes useful to examine the sentiment of large-scale investors toward Cue Biopharma Inc stocks. The insider ownership of Cue Biopharma Inc is 0.75%, while institutional ownership is 23.54%. The most recent insider transaction that took place on Dec 16 ’24, was worth 30,900. In this transaction CHIEF EXECUTIVE OFFICER of this company bought 30,000 shares at a rate of $1.03, taking the stock ownership to the 164,578 shares.
Cue Biopharma Inc (CUE) Performance Highlights and Predictions
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.15 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 33.69% per share during the next fiscal year.
Cue Biopharma Inc (NASDAQ: CUE) Trading Performance Indicators
You can see what Cue Biopharma Inc (CUE) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 2.22. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 11.78.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.91, a number that is poised to hit -0.09 in the next quarter and is forecasted to reach -0.52 in one year’s time.
Technical Analysis of Cue Biopharma Inc (CUE)
Let’s dig in a bit further. During the last 5-days, its volume was 0.58 million. That was inferior than the volume of 0.9 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 66.70%. Additionally, its Average True Range was 0.15.
During the past 100 days, Cue Biopharma Inc’s (CUE) raw stochastic average was set at 61.07%, which indicates a significant decrease from 75.81% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 124.87% in the past 14 days, which was lower than the 150.35% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $1.2764, while its 200-day Moving Average is $1.2295. However, in the short run, Cue Biopharma Inc’s stock first resistance to watch stands at $1.5990. Second resistance stands at $1.8079. The third major resistance level sits at $2.0759. If the price goes on to break the first support level at $1.1221, it is likely to go to the next support level at $0.8541. Assuming the price breaks the second support level, the third support level stands at $0.6452.
Cue Biopharma Inc (NASDAQ: CUE) Key Stats
There are 63,350K outstanding shares of the company, which has a market capitalization of 112.30 million. As of now, sales total 5,490 K while income totals -50,730 K. Its latest quarter income was 3,340 K while its last quarter net income were -8,660 K.
